Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dapagliflozin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    145 result(s) found for: Dapagliflozin. Displaying page 6 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2015-003818-24 Sponsor Protocol Number: DC2015RED01 Start Date*: 2015-12-11
    Sponsor Name:VU University Medical Center
    Full Title: A phase 4, monocenter, randomized, double-blind, comparator-controlled, parallel-group, mechanistic intervention trial to assess the effect of 12-week treatment with the sodium-glucose linked trans...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000420-38 Sponsor Protocol Number: 2021-01755 Start Date*: 2023-09-18
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Dapagliflozin in patients with Right Heart Failure (Dapa-RHF)
    Medical condition: Right heart failure defined as (criteria a-c must all be fulfilled): a) Reduced right ventricular systolic function or RV strain defined as at least one of the following b) N-terminal pro-BNP (NT...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000995-13 Sponsor Protocol Number: DECODE-CKD Start Date*: 2022-01-26
    Sponsor Name:Department of Cardiology, Herlev and Gentofte hospital
    Full Title: A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006787-25 Sponsor Protocol Number: 16122021 Start Date*: 2022-07-06
    Sponsor Name:Rigshospitalet The Heart Center
    Full Title: Effects of DAPAgliflozin on cardiopulmonary exercise capacity and hemodynamics in Pulmonary Arterial Hypertension: A double blind randomized trial
    Medical condition: Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10065150 Associated with pulmonary arterial hypertension LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10065151 Idiopathic pulmonary arterial hypertension LLT
    24.1 10010331 - Congenital, familial and genetic disorders 10085244 Heritable pulmonary arterial hypertension PT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10068740 CTEPH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004674-97 Sponsor Protocol Number: MB102-229 Start Date*: 2015-01-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed) FI (Completed) IT (Completed) DE (Completed) AT (Completed) ES (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002824-18 Sponsor Protocol Number: 8-311-3-062 Start Date*: Information not available in EudraCT
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A PHASE II, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE CENTER STUDY OF THE EFFECTS OF DAPAGLIFLOZIN VS PLACEBO ON ENDOGENOUS GLUCOSE PRODUCTION IN RENAL TRANSPLANT SUBJECTS WI...
    Medical condition: RENAL TRANSPLANT SUBJECTS WITH OR WITHOUT TYPE 2 DIABETES AND TYPE 2 DIABETIC SUBJECTS WITH NORMAL RENAL FUNCTION
    Disease: Version SOC Term Classification Code Term Level
    21.0 10042613 - Surgical and medical procedures 10038533 Renal transplant PT
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001921-33 Sponsor Protocol Number: MB102-029 Start Date*: 2008-09-08
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase 2 Trial to Evaluate the Glycemic Efficacy, Renal Safety, Pharmacokinetics, and Pharmacodynamics of Dapagliflozin i...
    Medical condition: DIABETES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001324-18 Sponsor Protocol Number: 202100178 Start Date*: 2021-09-30
    Sponsor Name:University Medical Center Groningen
    Full Title: A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients with elevated Albuminuria: a Randomized Double Blind Cross-Over Trial
    Medical condition: Patients with elevated Albuminuria
    Disease: Version SOC Term Classification Code Term Level
    27.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    27.0 10027433 - Metabolism and nutrition disorders 10016807 Fluid retention PT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019797-32 Sponsor Protocol Number: MB102-073 Start Date*: 2010-09-30
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects with Type 2 Diabetes with inadequately c...
    Medical condition: Men and women with type 2 diabetes, ages ≥ 18 to ≤ 89 years, who have type 2 diabetes with inadequately controlled hypertension.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10045242 Type II diabetes mellitus LLT
    14.1 100000004866 10066860 Uncontrolled hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) CZ (Completed) FI (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2009-010221-39 Sponsor Protocol Number: MB102035 Start Date*: 2009-12-18
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Exploratory Phase 2 Study to Assess the Effect of Dapagliflozin on Glomerular Filtration Rate (GFR) in Subjects with Type 2 Diabetes who have Inadequate Glycemic and Blood Pressure (BP) Control ...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    12.0 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005549-30 Sponsor Protocol Number: ESR-15-11421 Start Date*: 2016-02-17
    Sponsor Name:Dept of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University
    Full Title: A single-dose cross-over study to assess direct and indirect effects of dapagliflozin on pancreatic alpha and beta cells in patients with type 2 diabetes
    Medical condition: Effects on pancreatic alpha and beta cells in patients with type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005288-17 Sponsor Protocol Number: ESR-15-10964 Start Date*: 2016-04-05
    Sponsor Name:ΕΛΛΗΝΙΚΗ ΕΤΑΙΡΕΙΑ ΙΑΤΡΙΚΗΣ ΕΚΠΑΙΔΕΥΣΗΣ (Hellenic Society of Medical Education)
    Full Title: A study of the effects of dapagliflozin on ambulatory aortic pressure, arterial stiffness and urine albumin excretion in patients with type 2 diabetes.
    Medical condition: A study of the effects of dapagliflozin on ambulatory aortic pressure, arterial stiffness and urine albumin excretion in patients with type 2 diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    18.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2022-002721-99 Sponsor Protocol Number: CT114-2022-01 Start Date*: 2023-03-28
    Sponsor Name:Klinikum Nürnberg
    Full Title: Natriuretic-ureothelic adaptation of body fluid homeostasis during SGLT-2 inhibition and/or mineralocorticoid receptor modulation in patients with chronic kidney disease. A 4-arm, double-blind, dou...
    Medical condition: Stage 3 chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004599-49 Sponsor Protocol Number: MB102-230 Start Date*: 2015-08-31
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects with Type...
    Medical condition: Type 1 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DE (Completed) NL (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016791-71 Sponsor Protocol Number: D1690C00018 Start Date*: 2010-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled phase III study with an 80-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg once...
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000841-28 Sponsor Protocol Number: DC2017DECREASE01 Start Date*: 2017-08-14
    Sponsor Name:VU University Medical Center
    Full Title: Combined effects of SGLT2 inhibition and GLP-1 receptor agonism on food intake, body weight and central satiety and reward circuits in obese T2DM patients
    Medical condition: Type 2 diabetes mellitus Obesity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004913-93 Sponsor Protocol Number: D1690C00012 Start Date*: 2009-01-23
    Sponsor Name:AstraZeneca AB
    Full Title: A 24-week, Multi-centre, International, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study with a 78-week Extension Period to Evaluate the Effect of Dapagliflozin in Comb...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SE (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-004271-14 Sponsor Protocol Number: DAPAS Start Date*: 2021-12-06
    Sponsor Name:Aarhus University Hospital, department of Cardiology
    Full Title: Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis intervention
    Medical condition: Patients with aortic stenosis undergoing trans catheter aortic valve replacement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10058186 Aortic valve stenosis and insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004835-26 Sponsor Protocol Number: D169AL00005 Start Date*: 2021-05-24
    Sponsor Name:IRCCS-A.O.U. SAN MARTINO-IST
    Full Title: Single-center, randomized, controlled study to evaluate the effects of a six-month treatment with renal glucose transport inhibitor (SGLT2i) drugs on markers of senescence, inflammation and tubuloi...
    Medical condition: Chronic Kidney Deseas
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10050441 Chronic renal insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001167-24 Sponsor Protocol Number: TRS-2019-00002051 Start Date*: 2021-11-04
    Sponsor Name:SID - Società Italiana di Diabetologia e Malattie del Metabolismo
    Full Title: Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes. A pragmatic, phase IV, multicenter, open-label, randomised controlled trial.
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045252 Type II diabetes mellitus without mention of complication LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 28 23:57:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA